RxDoctor Payments DataLook up a doctor →

Aaron Doheny, APRN

Oncology · St Petersburg, FLNPI 1730532854

Payments from drug & device makers

$14,411in general payments, 2019–2025

Across 608 payments — averaging $23.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Johnson & Johnson$1K
  • Daiichi Sankyo Inc.$797
  • Pfizer$782
  • Gilead$656
  • AstraZeneca$630
  • plus $7K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis84$3,071
Johnson & Johnson(2 entities)57$1,000
Daiichi Sankyo Inc.31$797
Pfizer34$782
Gilead(2 entities)30$656
AstraZeneca(2 entities)33$630
Takeda Pharmaceuticals U.S.A., Inc.22$528
Lilly USA, LLC21$523
Merck20$466
Incyte Corporation16$392
Eisai Inc.17$380
E.r. Squibb & Sons, L.L.C.15$302
Bayer13$246
GSK9$235
Astellas Pharma US Inc10$216
AbbVie9$208
Bristol Myers Squibb11$206
Genentech USA, Inc.10$197
Stemline Therapeutics Inc.7$193
Pharmacyclics LLC, An Abbvie Company8$188
EMD Serono, Inc.8$183
Sobi, Inc9$182
Tersera Therapeutics LLC4$142
Seagen Inc.8$141
Array Biopharma Inc8$137
Pharmaessentia USA Corporation5$126
Springworks Therapeutics, Inc.5$126
Karyopharm Therapeutics Inc.6$119
Dendreon Pharmaceuticals LLC4$113
Amgen6$111
Jazz Pharmaceuticals Inc.5$110
Sumitomo Pharma America, Inc.5$110
AVEO Pharmaceuticals, Inc.6$108
Blueprint Medicines Corporation5$103
Puma Biotechnology, Inc.5$94
Adaptive Biotechnologies Corporation3$92
Pharmacosmos Therapeutics Inc.4$89
Taiho Oncology, Inc.4$84
Rigel Pharmaceuticals, Inc.4$75
Fennec Pharmaceuticals, Inc.3$72
Regeneron Healthcare Solutions, Inc.2$68
Geron Corporation3$64
ADC Therapeutics America, Inc.3$58
Ipsen Biopharmaceuticals, Inc3$52
Sanofi3$51
CSL Behring3$49
Beigene USA, Inc.2$47
Mirati Therapeutics, Inc.2$44
G1 Therapeutics, Inc.2$41
Myovant Sciences Inc.2$40
Novo Nordisk2$39
Boehringer Ingelheim2$34
Kyowa Kirin, Inc.2$32
Genmab U.S., Inc.1$29
Servier Pharmaceuticals LLC1$24
Syndax Pharmaceuticals, Inc.1$24
Deciphera Pharmaceuticals Inc.1$24
CTI Biopharma Corp.1$21
Exelixis Inc.1$20
Myriad Genetic Laboratories, Inc.1$20

How this compares

$14,411 in reported general payments places this provider in the 80th percentile of 24 oncology providers in Florida.

See all oncology providers in Florida →

Medicare billing

Part B allowed, 2024
$10,552
Medicare patients
12
Services billed
650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other oncology in St Petersburg

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →